Cerebral microvascular dysfunction in humanized APOE4 knock-in mice
Active Grant Awarded
- Award ID
- FAG101924U6P7B9
- Recipient
-
University Of Arizona UEI ED44Y3W6P7B9 Part of Arizona Board Of Regents
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $43,487
Award facts
- Assistance listing
- 93.AG4 National Institute on Aging Training Individual Projects
- Completion date 1% complete
- Place of performance
- Tucson, AZ 85724, USA
Award details come from USAspending.gov.
Description
- Abstract
- Cerebral small vessel disease (CSVD) is the most common cerebral vascular disorder, accounting for approximately 20% of all strokes and dementia cases worldwide. CSVD is characterized by damage to cerebral arterioles, which increases the incidence of cerebral microbleeds, microinfarcts and vasogenic edema, pathological hallmarks of CSVD. Further, CSVD is associated with development of alzheimer's disease (ad). Despite these associations, a mechanistic understanding of how CSVD may lead to dementia is lacking. Cerebral arterioles account for ~40% of the cerebral vascular resistance, protecting the downstream capillary bed against increases in intraluminal pressure. They do so via autoregulation, a vital process where cerebral arterioles constrict as intraluminal pressure increases. If cerebral arteriolar autoregulation fails, downstream vessels will be subjected to high intravascular pressure, leading to microbleeds and edema. Autoregulation is dependent on the intrinsic ability of vascular smooth muscle cells (VSMC) to contract, which requires CA2+ influx via opening of L-type voltage-gated CA2+ channels (CAV1.2). Thus, reductions in CAV1.2 function will impair autoregulation and may underlie CSVD. The E4 allele of apolipoprotein E (APOE4) is a significant genetic risk factor for CSVD. APOE4 disrupts cellular lipid metabolism and transport, leading to elevated cholesterol levels in cells. In the cerebral circulation, APOE is highly expressed in VSMC, but whether APOE4-dependent increases in VSMC cholesterol affect CAV1.2 function and cerebral autoregulation, thus increasing the risk of developing CSVD, remain undetermined. Our preliminary data strongly suggests that: 1) cholesterol reduces CAV1.2 activity in cerebral arteriolar VSMC; 2) cholesterol levels are increased in cerebral arterioles of humanized APOE4 knock-in mice (HAPOE4) and underlie blunted contractile and autoregulatory responses; 3) removal of VSMC cholesterol restores cerebral arteriolar CAV1.2 function and contractility. These exciting data lead to the overarching hypothesis of this proposal, which is that APOE4-mediated increases in membrane cholesterol in cerebral arteriolar VSMC leads to a reduction in CAV1.2 activity, thus impairing cerebral autoregulation and increasing the risk for CSVD. We will test this hypothesis using the following aims: aim 1: elevated membrane cholesterol impairs CAV1.2 channel function and disrupts cerebral arteriolar autoregulation. Aim 2: APOE4 expression increases membrane cholesterol in cerebral arteriolar vsmcs and contributes to impaired autoregulation. Aim 3: novel cholesterol lowering therapeutic restores arteriolar vsmcs CAV1.2 channel activity.
Quick answers
Who received award FAG101924U6P7B9?
FAG101924U6P7B9 was awarded to University Of Arizona by National Institute on Aging (National Institutes of Health) on November 18, 2026.
How much is award FAG101924U6P7B9 worth?
$43,487 has been obligated on FAG101924U6P7B9.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award